Revenue has effectively ceased since 2025Q1, while operating losses have expanded to $24.4 million in 2026Q1 due to rising R&D expenditures.
| Sales/Revenue | 0 | 0 | 251K | 33.49M | 4.93M | 2M | 0 |
| Revenue Growth % | - | -100% | -99.25% | 579.21% | 146.3% | - | - |
| Cost of Goods Sold | 666K | 2.6M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -666K | -2.6M | 251K | 33.49M | 4.93M | 2M | 0 |
| Gross Margin % | - | - | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | -1134.66% | -99.25% | 579.21% | 146.3% | - | - |
| Operating Expenses | 91.4M | 88.01M | 67.53M | 64.16M | 64.76M | 55.27M | 18.27M |
| OpEx % of Revenue | - | - | 26905.58% | 191.58% | 1313.32% | 2760.94% | - |
| Selling, General & Admin | 20.27M | 20.27M | 17.2M | 13.91M | 20.78M | 12.86M | 4.43M |
| SG&A % of Revenue | - | - | 6854.58% | 41.54% | 421.33% | 642.56% | - |
| Research & Development | 71.8M | 69.54M | 50.33M | 50.25M | 43.98M | 42.41M | 13.85M |
| R&D % of Revenue | - | - | 20051% | 150.04% | 891.99% | 2118.38% | - |
| Other Operating Expenses | -666K | -1.8M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -92.07M | -90.61M | -67.28M | -30.67M | -59.83M | -53.27M | -18.27M |
| Operating Margin % | - | - | -26805.58% | -91.58% | -1213.32% | -2660.94% | - |
| Operating Income Growth % | - | -34.67% | -119.37% | 48.74% | -12.31% | -191.57% | - |
| EBITDA | -89.43M | -88.01M | -64.85M | -28.41M | -58.67M | -53.02M | -18.2M |
| EBITDA Margin % | - | - | -25837.05% | -84.81% | -1189.84% | -2648.55% | - |
| EBITDA Growth % | -23.37% | -35.72% | -128.31% | 51.59% | -10.65% | -191.37% | - |
| D&A (Non-Cash Add-back) | 2.63M | 2.6M | 2.43M | 2.27M | 1.16M | 248K | 73K |
| EBIT | -92.07M | -90.61M | -67.28M | -30.67M | -59.83M | -71.83M | -17.59M |
| Net Interest Income | 5.01M | 5.96M | 5.35M | 2.54M | 1.29M | 0 | -197K |
| Interest Income | 5.01M | 5.96M | 5.35M | 2.54M | 1.29M | 0 | 2K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 199K |
| Other Income/Expense | 5M | 6.75M | 8.79M | 3.05M | 1.49M | -18.55M | 280K |
| Pretax Income | -87.07M | -83.86M | -58.49M | -27.62M | -58.34M | -71.83M | -17.99M |
| Pretax Margin % | - | - | -23303.98% | -82.48% | -1183.03% | -3587.66% | - |
| Income Tax | 0 | 0 | 0 | 72K | 53K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | -0.26% | -0.09% | 0% | 0% |
| Net Income | -87.07M | -83.86M | -58.49M | -27.7M | -58.39M | -71.83M | -17.99M |
| Net Margin % | - | - | -23303.98% | -82.69% | -1184.1% | -3587.66% | - |
| Net Income Growth % | -34.28% | -43.38% | -111.2% | 52.57% | 18.71% | -299.23% | - |
| Net Income (Continuing) | -87.07M | -83.86M | -58.49M | -27.7M | -58.39M | -71.83M | -17.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.53 | -3.43 | -5.20 | -1.19 | -3.32 | -4.08 | -1.02 |
| EPS Growth % | -11.29% | 34.04% | -336.97% | 64.16% | 18.63% | -300% | - |
| EPS (Basic) | - | -3.43 | -5.20 | -1.19 | -3.32 | -4.08 | -1.02 |
| Diluted Shares Outstanding | 24.68M | 24.44M | 24.36M | 23.28M | 17.58M | 17.58M | 17.58M |
| Basic Shares Outstanding | 24.68M | 24.44M | 24.36M | 23.28M | 17.58M | 17.58M | 17.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Clinical trial funding dependency
As indicated by the company's recent financial disclosures, Artiva has transitioned to a pre-revenue state following the cessation of historical collaboration-based income, with quarterly revenue figures dropping to zero since 2025Q1, underscoring the firm's total reliance on external capital to fund its ongoing clinical development programs.
The absence of top-line growth is a structural feature of the current business model rather than an operational failure, as the company prioritizes the advancement of its AB-101 pipeline. Investors should interpret this trajectory as a pure-play bet on clinical milestones, where future revenue potential remains entirely contingent on successful regulatory outcomes and commercialization partnerships.
Based on reported income statements, Artiva's R&D expenditures have steadily climbed from $11.2 million in 2024Q1 to $19.3 million by 2026Q1, reflecting the intensifying costs associated with executing multi-indication clinical trials and maintaining the specialized manufacturing supply chain required for its off-the-shelf NK cell platform.
The consistent upward trend in R&D spending suggests that the company is scaling its clinical footprint, which necessitates higher cash outflows for trial site management and patient enrollment. This expense discipline is secondary to the imperative of reaching data readouts, implying that cost management will likely remain secondary to clinical progress for the foreseeable future.
According to the provided quarterly data, operating losses have widened from $14.5 million in 2024Q1 to $24.4 million in 2026Q1, demonstrating that the company currently lacks the operational scale to offset its fixed overhead through any form of recurring revenue or margin-generating commercial activity.
The widening gap between R&D investment and operating income indicates that the company is in a high-burn phase of its lifecycle. Without a commercial product to provide operating leverage, the firm remains highly sensitive to the efficiency of its clinical trial execution, as any delays directly exacerbate the rate of capital depletion.
As reported in financial statements, Artiva's net losses have consistently tracked with its R&D intensity, with the 2026Q1 net loss of $23.5 million highlighting the significant capital requirements necessary to sustain the company's current therapeutic development pipeline in the absence of any offsetting commercial revenue streams.
The quality of these earnings is defined by the nature of the R&D-heavy cost structure, which is typical for early-stage biotechnology firms. Analysts should monitor the impact of stock-based compensation, which, while currently modest, represents a potential source of future dilution that could further impact the per-share value for existing equity holders.
Based on the reported figures, the company's reliance on equity financing to cover its $20M+ quarterly operating losses warrants caution, as the competitive intensity in the B-cell depletion space may force higher spending levels than currently anticipated to maintain a viable position against better-capitalized industry peers.
Short-term observers may point to the risk that the current cash runway is insufficient to reach definitive clinical proof-of-concept, potentially necessitating dilutive capital raises at unfavorable valuations. The market's skepticism regarding the durability of non-engineered NK cells compared to CAR-T alternatives remains a fundamental risk that could limit the company's future access to capital markets.
Quick answers to the most common questions about buying ARTV stock.
For fiscal year 2025, Artiva Biotherapeutics, Inc. (ARTV) reported total revenue of $0.0M.
Artiva Biotherapeutics, Inc. (ARTV) reported a net loss of $83.9M for the fiscal year ending 2025.